The Membrane Molecule That Keeps Changing Its Story

So here's a sentence nobody expects to need: the fatty yellow molecule that keeps every cell membrane you own from leaking — the lecithin in your eggs and soybeans, the stuff your liver manufactures to package and export its own fat, the principal dietary form of choline and therefore, a few enzymatic steps later, of the neurotransmitter acetylcholine — is the same molecule, give or take a purification step, that supplement companies sell as a liver cure-all, that pharmaceutical chemists spent two decades engineering into a delayed-release colon tablet for ulcerative colitis, and that your gut bacteria (this is the awkward part, so hold on to it) convert into a metabolite that large human cohorts keep associating with cardiovascular events and earlier death.

All of those phosphatidylcholines are real, and they do not reconcile into one tidy story, which is exactly why the molecule is worth a reader's skepticism. The honest question: what has phosphatidylcholine actually been shown to do in humans, and where does the record dissolve into mechanism and hope?

The colitis program that soared, then didn't

The most encouraging human evidence belongs to gastroenterology, not the supplement aisle. In a randomized trial published in Annals of Internal Medicine in 2007, delayed-release phosphatidylcholine — engineered to survive the stomach and coat the inflamed colon — outperformed placebo in patients whose chronic ulcerative colitis had not responded to steroids. A 2021 meta-analysis in Digestive Diseases pooled the delayed-release trials and found higher remission and endoscopic-improvement rates than placebo. That is a genuinely impressive arc for a membrane lipid. Then the pivotal modern program, a formulation called LT-02, failed both of its large phase 3 trials in 2024. Whether this molecule is a medicine for colitis is, as of today, an unresolved question with two contradictory answers, and the bigger, better-funded answer is the negative one.

The liver, the brain, and a stack of nulls

Purified "essential phospholipids" are widely used for liver disorders, and smaller studies do report improvements in some biochemical and steatosis measures. But the large Veterans Affairs randomized trial found no effect on the progression of alcoholic liver fibrosis — the outcome that actually matters — and a trial of a nutraceutical mixture in fatty liver disease showed no efficacy. For the brain, a Cochrane review of 12 trials found no clear benefit of lecithin for dementia or cognitive impairment. A 2025 study linking lecithin intake to protection against combined sarcopenia and cognitive decline, through a proposed muscle-to-brain signaling pathway, is intriguing and unreplicated — a hypothesis wearing a lab coat, not a result.

The mitochondrial aging headline, handled carefully

A 2026 paper in Nature Communications argues that the age-associated decline in phosphatidylcholine synthesis acts as a "malleable trigger" of natural mitochondrial aging, and earlier work in the Journal of Membrane Biology documented ageing-induced shifts in the lipid profiles of brain and liver mitochondria. This is real and interesting biology about why membranes age. It is not a human trial showing that swallowing phosphatidylcholine slows anything. Meanwhile, choline adequacy is a legitimate nutritional question — a 2016 assessment of American choline intakes using NHANES data exists precisely because intake is uncertain — but adequacy from food is a different claim than supplementation for longevity.

The complication the label won't mention

Gut microbiota convert dietary phosphatidylcholine into trimethylamine-N-oxide — TMAO — and large human cohorts associate higher TMAO levels with increased cardiovascular and all-cause mortality. That is an association, not proof that a lecithin capsule harms anyone. But it means "more of a membrane building block" is not automatically benign, and it has never been resolved in trials. One further caution: oral supplements share a name with unapproved injectable "fat-dissolving" phosphatidylcholine products that have drawn FDA safety warnings. They are not the same thing, and the injection story is not evidence about the capsule — but the confusion is common enough to be worth stating plainly.

What to do with a molecule this complicated

Eggs, soybeans, liver, and meat deliver choline in the form the human diet has always provided, and no trial has shown the supplement version prevents disease in healthy people. The colitis program, whatever its future, was a prescription-grade drug effort with a defined dose and release mechanism — nothing about it validates a lecithin capsule for a healthy gut. The molecule that seals your membranes turns out to be a story about the difference between a nutrient and a drug, and between a mechanism and a result. Educational, not medical advice.